Successful implementation of outpatient R ± DHAX (rituximab, dexamethasone, oxaliplatin, cytarabine) for select patients with lymphoma: a single-center experience. Issue 4 (21st March 2022)
- Record Type:
- Journal Article
- Title:
- Successful implementation of outpatient R ± DHAX (rituximab, dexamethasone, oxaliplatin, cytarabine) for select patients with lymphoma: a single-center experience. Issue 4 (21st March 2022)
- Main Title:
- Successful implementation of outpatient R ± DHAX (rituximab, dexamethasone, oxaliplatin, cytarabine) for select patients with lymphoma: a single-center experience
- Authors:
- Pak, Terry K.
Dixon, Brianne N.
Buege, Michael J.
Dao, Phuong H.
Leary, Megan H.
Jarrett, Joy C.
Duggan, Tara A.
Caron, Philip
Falchi, Lorenzo
Hamlin, Paul
Hamilton, Audrey
Matasar, Matthew J.
Moskowitz, Alison
Noy, Ariela
Owens, Colette N.
Von Keudell, Gottfried
Younes, Anas
Zelenetz, Andrew D.
Kumar, Anita - Abstract:
- Abstract: R ± DHAX has been traditionally administered to inpatient due to the timing of chemotherapy administration and the perceived need for close monitoring of adverse effects. To administer R ± DHAX outpatient, a multidisciplinary task force created clinical and educational guidelines which were implemented through two phases: pilot and expansion. The pilot program determined the feasibility of transitioning R ± DHAX outpatient at a single infusion site. The expansion phase led to a service-wide implementation across all outpatient sites. A total of 40 patients were included, of which 23 patients completed all cycles, outpatient, 12 transitioned inpatient to outpatient administration, and 5 transitioned outpatient to inpatient administration. The success rate of outpatient R ± DHAX administration was 90% (36 patients successfully completed outpatient administration/40 total patients). No cytarabine-related cerebellar or ophthalmic toxicity was reported. Outpatient R ± DHAX saved 192 hospital days. R ± DHAX could be successfully administered outpatient with minimal safety concerns and reduced hospital bed utilization.
- Is Part Of:
- Leukemia & lymphoma. Volume 63:Issue 4(2022)
- Journal:
- Leukemia & lymphoma
- Issue:
- Volume 63:Issue 4(2022)
- Issue Display:
- Volume 63, Issue 4 (2022)
- Year:
- 2022
- Volume:
- 63
- Issue:
- 4
- Issue Sort Value:
- 2022-0063-0004-0000
- Page Start:
- 876
- Page End:
- 884
- Publication Date:
- 2022-03-21
- Subjects:
- Non-Hodgkin lymphoma -- chemotherapy -- R ± DHAX -- outpatient -- patient satisfaction -- quality improvement
Leukemia -- Periodicals
Lymphomas -- Periodicals
616.99419 - Journal URLs:
- http://informahealthcare.com ↗
- DOI:
- 10.1080/10428194.2021.2002318 ↗
- Languages:
- English
- ISSNs:
- 1042-8194
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 5185.251500
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 21297.xml